[1]张梓宸.前列地尔治疗冠心病心绞痛的疗效[J].医学信息,2020,33(01):149-150.[doi:10.3969/j.issn.1006-1959.2020.01.048]
　ZHANG Zi-chen.Effect of Alprostadil in the Treatment of Coronary Heart Disease and Angina Pectoris[J].Medical Information,2020,33(01):149-150.[doi:10.3969/j.issn.1006-1959.2020.01.048]
点击复制

前列地尔治疗冠心病心绞痛的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年01期
页码:
149-150
栏目:
药物与临床
出版日期:
2020-01-01

文章信息/Info

Title:
Effect of Alprostadil in the Treatment of Coronary Heart Disease and Angina Pectoris
文章编号:
1006-1959（2020）01-0149-02
作者:
张梓宸
（佳木斯市中心医院心内科，黑龙江 佳木斯 154002）
Author(s):
ZHANG Zi-chen
(Department of Cardiology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
前列地尔; 冠心病心绞痛; 血管内皮功能; 炎症反应
Keywords:
Alprostadil; Coronary heart disease angina pectoris; Vascular endothelial function;  Inflammatory response
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2020.01.048
文献标志码:
A
摘要:
目的 探讨前列地尔治疗冠心病心绞痛的疗效及对患者血管内皮功能的影响。方法 选取2018年1月~2019年1月我院收治的68例冠心病心绞痛患者作为研究对象，按照随机数字表法分为观察组和对照组，各34例。对照组给予常规治疗，观察组在对照组基础上给予前列地尔治疗，比较两组治疗总有效率、血清超敏C反应蛋白（hs-CRP）、一氧化氮（NO）、内皮素（ET-1）以及不良反应发生率。结果 观察组治疗总有效率为97.06%，高于对照组的76.47%（P＜0.05）；治疗后，观察组hs-CRP、ET-1低于对照组，NO高于对照组（P＜0.05）；两组不良反应发生率比较（P＞0.05）。结论 前列地尔治疗冠心病心绞痛可提升临床疗效，减少患者心绞痛发作次数，减轻患者炎症反应，提高血管内皮功能。
Abstract:
Objective To investigate the effect of alprostadil on angina pectoris of coronary heart disease and its effect on vascular endothelial function. Methods From January 2018 to January 2019, 68 patients with angina pectoris of coronary heart disease treated in our hospital were selected as the research objects, and they were divided into observation group and control group according to the random number table method, with 34 cases each. The control group was given conventional treatment. The observation group was given alprostadil on the basis of the control group. The total effective rate, serum high-sensitivity C-reactive protein (hs-CRP), nitric oxide (NO), and endothelin (ET -1) and the incidence of adverse reactions. Results The total effective rate of treatment in the observation group was 97.06%, which was higher than 76.47% in the control group (P<0.05). After treatment, hs-CRP and ET-1 in the observation group were lower than the control group, and NO was higher than the control group (P＜ 0.05); Comparison of the incidence of adverse reactions between the two groups (P>0.05). Conclusion Alprostadil treatment of coronary heart disease and angina pectoris can improve clinical efficacy, reduce the number of angina pectoris episodes, reduce inflammation and improve vascular endothelial function.

参考文献/References:

[1]王超,王利红,刘宝,等.前列地尔注射液对老年不稳定型心绞痛病人临床症状、心电图及血常规的影响[J].中西医结合心脑血管病杂志,2018,16(9):1239-1241. [2]周衍国,麦瑞林,黄敏旋,等.前列地尔对冠心病患者血浆内皮素、同型半胱氨酸和凝血功能的影响[J].海南医学,2018,29(7):917-919. [3]邹振强,巫少荣,陈小明,等.前列地尔对微血管性心绞痛患者血管内皮功能的影响[J].广东医学,2018,39(4):622-623. [4]冯六六,黄红漫,刘新兵,等.冠心病患者血清hsCRP水平和外周血单个核细胞CX3CR1的表达及其临床意义[J].心血管康复医学杂志,2018,27(2):12-16.

相似文献/References:

[1]岳卫东.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床研究[J].医学信息,2018,31(21):141.[doi:10.3969/j.issn.1006-1959.2018.21.040]
　YUE Wei-dong.Clinical Study of Trimetazidine Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Angina Pectoris with Dyslipidemia[J].Medical Information,2018,31(01):141.[doi:10.3969/j.issn.1006-1959.2018.21.040]
[2]郭 婵.前列地尔对慢性肾功能衰竭患者血清炎症因子水平及营养生化指标的影响[J].医学信息,2022,35(13):146.[doi:10.3969/j.issn.1006-1959.2022.13.035]
　GUO Chan.Effect of Alprostadil on Serum Inflammatory Factors and Nutritional Biochemical Indexes in Patients with Chronic Renal Failure[J].Medical Information,2022,35(01):146.[doi:10.3969/j.issn.1006-1959.2022.13.035]
[3]张文航.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴 血脂异常的临床疗效[J].医学信息,2019,32(18):144.[doi:10.3969/j.issn.1006-1959.2019.18.049]
　ZHANG Wen-hang.Clinical Efficacy of Trimetazidine Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Angina Pectoris with Dyslipidemia[J].Medical Information,2019,32(01):144.[doi:10.3969/j.issn.1006-1959.2019.18.049]
[4]周忠梅.前列地尔辅助常规治疗冠心病不稳定型心绞痛的效果及对患者凝血功能的影响[J].医学信息,2019,32(20):147.[doi:10.3969/j.issn.1006-1959.2019.20.046]
　ZHOU Zhong-mei.Effect of Alprostadil on Routine Treatment of Unstable Angina Pectoris in Coronary Heart Disease and its Effect on Coagulation Function in Patients[J].Medical Information,2019,32(01):147.[doi:10.3969/j.issn.1006-1959.2019.20.046]
[5]吴 飞,余 路.尿毒清颗粒及前列地尔联合丹参酮治疗糖尿病肾病的疗效[J].医学信息,2019,32(13):153.[doi:10.3969/j.issn.1006-1959.2019.13.048]
　WU Fei,YU Lu.Therapeutic Effect of Urinary Granules and Alprostadil Combined with Tanshinone on Diabetic Nephropathy[J].Medical Information,2019,32(01):153.[doi:10.3969/j.issn.1006-1959.2019.13.048]
[6]王 力,袁志强,黄晓鹏,等.前列地尔联合缬沙坦对慢性肾小球肾炎患者肾功能指标的影响[J].医学信息,2019,32(21):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
　WANG Li,YUAN Zhi-qiang,HUANG Xiao-peng,et al.Effect of Alprostadil Combined with Valsartan on Renal Function Indexes in Patients with Chronic Glomerulonephritis[J].Medical Information,2019,32(01):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
[7]袁 娟,赫英龙.参芎葡萄糖与前列地尔治疗慢性肾脏病的疗效比较[J].医学信息,2020,33(14):163.[doi:10.3969/j.issn.1006-1959.2020.14.053]
　YUAN Juan,HE Ying-long.Comparison of Curative Effect between Shenqiong Glucose and Alprostadil in Treating Chronic Kidney Disease[J].Medical Information,2020,33(01):163.[doi:10.3969/j.issn.1006-1959.2020.14.053]
[8]陈钰泱,石爱杰.缬沙坦联合前列地尔治疗慢性肾小球肾炎的效果[J].医学信息,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
　CHEN Yu-yang,SHI Ai-jie.The Effect of Valsartan Combined with Alprostadil on Chronic Glomerulonephritis[J].Medical Information,2020,33(01):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
[9]王 楠.前列地尔联合丁苯肽对缺血性脑卒中患者血清炎症因子及凝血功能的影响[J].医学信息,2021,34(12):169.[doi:10.3969/j.issn.1006-1959.2021.12.046]
　WANG Nan.Effects of Alprostadil Combined with Butylphthalide on Serum Inflammatory Factors and Coagulation Function in Patients with Ischemic Stroke[J].Medical Information,2021,34(01):169.[doi:10.3969/j.issn.1006-1959.2021.12.046]
[10]刘 超,甘佳乐,冯丽丽,等.刘红旭教授治疗冠心病心绞痛的临床经验[J].医学信息,2022,35(04):165.[doi:10.3969/j.issn.1006-1959.2022.04.044]

更新日期/Last Update: 2020-01-01